Emily Slopnick, MD
Urogynecology and Reconstructive Pelvic Surgery · Cleveland, OHNPI 1790043107
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $24,348 of the $36,761 with a category attached, or 66.2%. Medtronic accounts for 89.5% of it on its own, with 12 other manufacturers making up the rest. Among urogynecology and reconstructive pelvic surgery clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 237 payments — averaging $155.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$33K
- AbbVie$1K
- Boston Scientific$1K
- Axonics, Inc.$722
- Coloplast$337
- Astellas Pharma US Inc$222
- plus $394 from 7 others
Across 3 payments — averaging $3535.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$10K
- Medtronic$355
What the payments were for
- Consulting fees$2631%
- Speaking & faculty fees$24,34866%
- Travel & lodging$2,3576%
- Food & beverage$9,64326%
- Education$1510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 158 | $32,901 |
| AbbVie(2 entities) | 34 | $1,133 |
| Boston Scientific | 17 | $1,052 |
| Axonics, Inc. | 11 | $722 |
| Coloplast | 3 | $337 |
| Astellas Pharma US Inc | 5 | $222 |
| Urovant Sciences Inc | 3 | $145 |
| Teleflex LLC | 1 | $81 |
| Sumitomo Pharma America, Inc. | 1 | $63 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $38 |
| Rochester Medical Corporation | 1 | $26 |
| BD | 1 | $21 |
| Convatec Inc. | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INTERSTIM$30,264
- BOTOX$377
- ALTIS$299
- Axonics$256
- ADVANTAGE FIT$248
- Axonics r-SNM System$186
- BOTOX COSMETIC$114
- Bulkamid$111
- GENERAL PELVIC ORGAN PROLAPSE$110
- Advantage System$108
How this compares
$36,761 in reported general payments places this provider in the 90th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
See all urogynecology and reconstructive pelvic surgery providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 142 | $105,231 |
| GemtesaVibegron | 132 | $91,027 |
| Mirabegron ErMirabegron | 16 | $12,798 |
| Estradiol | 137 | $7,733 |
| Trospium Chloride | 116 | $6,544 |
| Trospium Chloride ErTrospium Chloride | 48 | $3,972 |
| Fesoterodine Fumarate ErFesoterodine Fumarate | 57 | $2,779 |
| Methenamine Hippurate | 35 | $2,621 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 52 | $760 |
| Cephalexin | 46 | $507 |
| NitrofurantoinNitrofurantoin Macrocrystal | 12 | $455 |
| Tamsulosin Hcl | 17 | $219 |
| Hydroxyzine Hcl | 11 | $204 |
| Fluconazole | 18 | $145 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 31 | $88 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $222 | $105,231142 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $63 | $91,027132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 60 urogynecology and reconstructive pelvic surgery providers in Ohio.
Other urogynecology and reconstructive pelvic surgery in Cleveland
- Ly Hoang RobertsCleveland$23K
- Marie ParaisoCleveland$20K
- Omer AnisCleveland$17K
- Chen ShenharCleveland$13K
- Amy ParkCleveland$11K
- Katie PropstCleveland$6K
- Anne SammarcoCleveland$5K
- Amy GeeCleveland$5K
- Shannon WallaceCleveland$5K
- Graham ChapmanCleveland$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.